摘要
目的:探讨重组牛碱性成纤维细胞生长因子与玻璃酸钠联合奥洛他定治疗儿童过敏性结膜炎合并异常瞬目的临床疗效。方法:研究对象为广州市花都区妇幼保健院胡忠医院2024年4月—2025年2月期间收治的82例过敏性结膜炎合并异常瞬目患儿,采用随机数表法分为重组组(41例)与玻璃酸钠组(41例)。重组组选择重组牛碱性成纤维细胞生长因子眼用凝胶联合奥洛他定局部治疗,玻璃酸钠组选择玻璃酸钠联合奥洛他定局部治疗,比较异常瞬目次数、泪膜破裂时间(BUT)。角膜荧光素染色试验(FL)、不良反应发生率与复发率。结果:两组治疗后的异常瞬目次数均显著降低,且重组组的降低幅度大于玻璃酸钠组(P<0.05)。两组治疗后的BUT均提高,FL评分均降低,且重组组的改变幅度大于玻璃酸钠组(P<0.05)。两组出现视物模糊、眼部刺痛、眼干等不良反应发生率与复发率均无统计学差异(P>0.05)。结论:重组牛碱性成纤维细胞生长因子、玻璃酸钠联合奥洛他定局部治疗均可显著改善儿童过敏性结膜炎合并异常瞬目患者的眼表健康状况,且复发率与并发症相当。但重组牛碱性成纤维细胞生长因子联合奥洛他定在提高泪膜稳定性、减少角膜上皮损伤方面的疗效更优,可在临床上推广。
Objective:To investigate the clinical efficacy of recombinant bovine basic fibroblast growth factor combined with sodium hyaluronate and olopatadine in the treatment of allergic conjunctivitis with abnormal blinking in children.Methods:The study subjects were 82 pediatric patients with allergic conjunctivitis combined with abnormal blinking who were admitted to Hu Zhong Hospital of Guangzhou Huadu District Maternal and Child Health Hospital from April 2024 to February 2025.The patients were randomly divided into two groups using the random number table method:the recombinant group(41 cases)and the sodium hyaluronate group(41 cases).The recombinant group received recombinant bovine basic fibroblast growth factor(rb-bFGF)ophthalmic gel combined with olopatadine for topical treatment,while the sodium hyaluronate group received sodium hyaluronate combined with olopatadine for topical treatment.The study compared the number of abnormal blinking episodes,tear film breakup time(BUT),corneal fluorescein staining test(FL),incidence of adverse reactions,and recurrence rate between the two groups.Results:Compared to before treatment,the number of abnormal blinks in both groups was significantly reduced,and the reduction was more pronounced in the recombinant group than in the sodium hyaluronate group(P<0.05).After treatment,both groups showed an increase in BUT and a decrease in FL score,with the changes being greater in the recombinant group compared to the sodium hyaluronate group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions,such as blurred vision,ocular stinging,and dry eyes,or in the recurrence rates between the two groups(P>0.05).Conclusion:Both recombinant bovine basic fibroblast growth factor(rb-bFGF)combined with olopatadine and sodium hyaluronate combined with olopatadine for topical treatment can significantly improve ocular surface health in pediatric patients with allergic conjunctivitis combined with abnormal blinking,with comparable recurrence rates and complications.However,rb-bFGF combined with olopatadine demonstrates superior efficacy in enhancing tear film stability and reducing corneal epithelial damage,making it a promising option for clinical application.
作者
董丽洁
杨巧玲
江丽君
Dong Lijie(Guangzhou Huadu Maternal and Child Health Hospital(Huzhong Hospital),Guangzhou Guangdong 510000)
出处
《黑龙江医药》
2025年第4期810-813,共4页
Heilongjiang Medicine journal
基金
广州市花都区科技计划项目(项目编号:24-HDWS-063)。
